Biointron, a Shanghai-based antibody contract research organization with offices in Cambridge, MA and Piscataway, NJ, has introduced RushMab™, a suite of small-scale antibody expression packages that ...

Biointron, an antibody contract research organization, launched a new developability platform that helps drug developers identify manufacturing problems early, potentially saving millions by catching ...

Although bsAb drugs are growing in popularity, scientists face several challenges when manufacturing these complex proteins. Co-expression of the selected heavy chains (HCs) and light chains (LCs) ...

Go to The Scientist's Facebook Page Go to The Scientist's Instagram Page Go to The Scientist's LinkedIn Page Go to The Scientist's Podcast Page Go to The Scientist's YouTube Page Effective gene ...

Therapeutic antibodies have become one of the fastest-growing drug classes used to treat cancer and autoimmune diseases. To find the most promising antibody, biotechnology and pharmaceutical companies ...

Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by decades of advances in discovery, engineering, and manufacturing. Many ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and rare ...